Adherence to antiretroviral therapy in HIV-infected children in Italy

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 11, Issue 6, 1999, Pages 711-714

  Albano, F ^a   Spagnuolo, M I ^a   Berni Canani, R ^a   Guarino, A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; ITALY; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; ITALY; MALE; PARENTS; PATIENT COMPLIANCE; RADIOIMMUNOASSAY; ZIDOVUDINE;

EID: 0033430911     PISSN: 09540121     EISSN: None     Source Type: Journal    
DOI: 10.1080/09540129947613     Document Type: Article

References (12)

1. BALIS, F.M., PIZZO, P.A., EDDY, J. et al. (1989). Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. Journal of Pediatrics, 114, 880-884.
2. BESCH, C.L. (1995). Compliance in clinical trials. AIDS, 9, 1-10.
3. CAMERON, W. (1997). Combining protease inhibitors for optimal HIV therapy. Sixth European Conference on Clinical Aspects and Treatment of HIV infection, Hamburg.
4. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) (1994). 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Morbidity Mortality Weekly Report, 43, 1-10.
5. GUARINO, A., ALBANO, F., CASTALDO, A., SPAGNUOLO, M.I. & BERNI CANANI, R. (1998). Intestinal malabsorption and zidovudine bioavailability. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 18, 91-92.
6. JAPOUR, A. (1997). Future aspects in protease inhibitor therapy. Sixth European Conference on Clinical Aspects and Treatment of HIV infection, Hamburg.
7. MCKINNEY, R.E., MAHA, M.A., CONNOR, E.M. et al. (1991). A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. New England Journal of Medicine, 324, 1018-1025.
8. MITSUYA, H., WEINNOD, K.J., FURMAN, P.A. et al. (1985). 3′-Azido-3′-deoxythymidine (BW A509U): a new antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotrophic virus type II/lymphoadenopathy-associated virus in vitro. Proceedings of the National Academy Sciences, USA, 82, 7096-7100.
9. MONTANER, J.S.G., RABOUD, J.M., RAE, S. FOR THE INCAS AND AVANTI STUDY GROUPS (1998a). Adherence to treatment increases duration of virological suppression regardless of pVL nadir. In Proceedings of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, September, San Diego, CA (abstract 191).
10. MONTANER, J.S.G., HOGG, R., RABOUD, J., HARRIGAN, R. & O'SHAUGHNESSY, M. (1998b). Antiretroviral treatment in 1998. Lancet, 352, 1919-1922.
11. SINGH, N., SQUIER, C., SIVEK, C., WAGENER, M., NGUYEN, M.H. & YU, V.L. (1996). Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care, 8, 261-269.
12. TUDOR-WILLIAMS, G., ST CLAIR, M.H., MCKINNEY, R.E. et al. (1992). HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet, 339, 15-19.